Picture of Edesa Biotech logo

EDSA — Edesa Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Edesa Biotech Inc expected to post a loss of 29  cents a share - Earnings Preview

* Edesa Biotech Inc  EDSA.OQ   EDSA.O  is expected to show a
fall in quarterly revenue when it reports results on May 13
(estimated) .
​* Refinitiv's mean analyst estimate for Edesa Biotech Inc is
for a loss of 29 cents per share. For the same quarter last
year, the company reported a loss of 17 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Edesa Biotech
Inc is $17​, about 64.6% above​ its last closing price
of $6.02. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.19       -0.19      -0.26     Missed  -36.8
 Sep. 30 2020  -0.21       -0.20      -0.22     Missed  -7.3
 Jun. 30 2020  -0.23       -0.20      -0.20     Met     2.4​
 Mar. 31 2020  -0.19       -0.19      -0.17     Beat    10.5
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated May 11 at 13:00 GMT.  All
figures in US dollars unless otherwise stated

Recent news on Edesa Biotech

See all news